Neuroendocrine Tumor Treatment Market Report 2026

The neuroendocrine tumor treatment market size has grown rapidly in recent years. It will grow from $2.39 billion in 2025 to $2.65 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to early adoption of somatostatin analogs, increasing incidence of neuroendocrine tumors, initial development of targeted therapies, growth in advanced diagnostic imaging, rising awareness of rare cancer categories.

The neuroendocrine tumor treatment market size is expected to see rapid growth in the next few years. It will grow to $3.98 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to growing investment in prrt innovations, increasing adoption of personalized oncology treatment, expansion of immunotherapy in net treatment, rising availability of oncology care centers, development of new combination chemotherapy regimens. Major trends in the forecast period include increasing use of somatostatin analogs for tumor growth control, growing adoption of targeted therapy options, rising utilization of chemotherapy in advanced net cases, expansion of peptide receptor radionuclide therapy (prrt), increasing demand for multidisciplinary oncology care.

The growing prevalence of neuroendocrine tumors is expected to drive the expansion of the neuroendocrine tumor treatment market in the coming years. Neuroendocrine tumors (NETs) are rare tumors that originate from neuroendocrine cells. Treating these tumors is crucial for symptom management, controlling tumor growth, and using radiation therapy to destroy tumor cells. For example, in 2024, NeuroEndocrine Cancer Australia (NECA), an Australia-based advocacy, education, and research organization, estimated that 21.1 per 100,000 people will be diagnosed with NETs, amounting to roughly 5,755 new cases, with a 39-year prevalence of approximately 29,351 individuals living with NETs. Consequently, the increasing incidence of neuroendocrine tumors is propelling the growth of the treatment market.

Major companies in the neuroendocrine tumor treatment market are focusing on developing advanced therapeutic options, such as radioligand therapies, to enhance clinical outcomes and broaden treatment possibilities for patients with GEP-NETs. Radioligand therapy is a targeted approach that delivers radioactive isotopes directly to tumor cells with specific receptors, allowing precise tumor destruction while sparing surrounding healthy tissue. For instance, in April 2024, Novartis, a Switzerland-based healthcare company, announced FDA approval for Lutathera, the first radioligand therapy specifically for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. This approval improves access to targeted radiopharmaceutical treatment for younger patients and highlights the growing importance of radioligand therapies in improving treatment efficacy, clinical decision-making, and patient care.

In March 2024, Merck & Co., Inc., a US-based pharmaceutical company, acquired Harpoon Therapeutics for approximately $650 million. Through this acquisition, Merck aims to expand and diversify its oncology pipeline by incorporating Harpoon’s next-generation T-cell engager technologies, which target hard-to-treat solid and neuroendocrine tumors. Harpoon Therapeutics is a US-based developer of innovative T-cell engager immunotherapies designed to treat cancers expressing specific targets.

Major companies operating in the neuroendocrine tumor treatment market are Pfizer Inc, F Hoffmann‑La Roche AG, Novartis AG, Sanofi SA, Takeda Pharmaceutical, Ipsen Pharma SAS, Jiangsu Hengrui Medicine, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, Ascentage Pharma, Debiopharm, Boehringer Ingelheim International GmbH, Hutchison MediPharma Ltd, Exelixis Inc, EpicentRx Inc, Tarveda Therapeutics, Teclison Ltd, Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals.

North America was the largest region in the neuroendocrine tumor treatment market in 2025. The regions covered in the neuroendocrine tumor treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuroendocrine tumor treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neuroendocrine tumor treatment market by increasing the costs of imported oncology drugs, radiopharmaceuticals, and diagnostic imaging equipment essential for detection and therapy. These added expenses particularly affect hospitals and oncology centers in regions reliant on imported cancer treatment components, including Europe and Asia-Pacific. Product segments such as somatostatin analogs, targeted therapy agents, and PRRT components experience higher procurement costs and supply delays. Nonetheless, tariffs are stimulating regional pharmaceutical manufacturing, encouraging local radiopharmaceutical production, and promoting innovation in cost-effective cancer treatment solutions.

The neuroendocrine tumor treatment market research report is one of a series of new reports that provides neuroendocrine tumor treatment market statistics, including neuroendocrine tumor treatment industry global market size, regional shares, competitors with a neuroendocrine tumor treatment market share, detailed neuroendocrine tumor treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neuroendocrine tumor treatment industry. This neuroendocrine tumor treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuroendocrine tumor treatment involves medical interventions and therapies designed to manage and control neuroendocrine tumors (NETs). Neuroendocrine tumors are a rare form of cancer that develop from neuroendocrine cells responsible for regulating hormone production in the body. Treatment for these tumors includes multiple strategies aimed at controlling tumor growth, alleviating symptoms, and enhancing the patient’s quality of life.

The primary categories of products used in neuroendocrine tumor treatment include somatostatin analogs (SSAs), targeted therapies, chemotherapy, and other options. Somatostatin analogs (SSAs) are synthetic drugs that replicate the effects of somatostatin, a naturally occurring hormone in the body. These drugs are indicated for use in conditions affecting the lungs, pancreas, gastrointestinal tract, and other areas. Key end-users of these treatments are hospitals, oncology centers, and related healthcare facilities.

The neuroendocrine tumor treatment market includes of revenues earned by entities by providing neuroendocrine tumor treatment services such as surgery, radiation therapy, peptide receptor radionuclide therapy, somatostatin analogs, diagnosis, staging and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.